| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Evommune, Inc.
13D/A
EVMN · 30054Y107
|
14.7% |
2/19/2026
Event 2/12/2026
|
||||
| LSP 7 Cooperatieve U.A. | 14.7% | |||||
| LSP 7 Management B.V. | 14.7% | |||||
|
AgomAb Therapeutics NV
13D
AGMB · 00860C102
|
10.6% |
2/17/2026
Event 2/9/2026
|
||||
| LSP 7 Cooperatieve U.A. | 10.6% | |||||
| LSP 7 Management B.V. | 10.6% | |||||
| Schedule 13G · 2 securities · passive | ||||||
|
Electra Therapeutics, Inc.
13G
ETRA · 284825106
|
6.0% |
9/28/2026
Event 9/21/2026
|
||||
| LSP 7 Cooperatief U.A. | 6.0% | |||||
| LSP 7 Management B.V. | 6.0% | |||||
|
Oculis Holding AG
13G/A
OCS · H5870P102
|
11.8% |
4/29/2026
Event 3/31/2026
|
||||
| LSP 7 Cooperatieve U.A. | 11.8% | |||||
| LSP 7 Management B.V. | 11.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.